Oceanyx has identified several novel and diverse chemical series from the marine cyanobacteria-based drug discovery initiatives for treating various diseases. One of the Companyâs lead molecules, largazole , is a novel and distinct class I histone deacetylase (HDAC) inhibitor, and is indicated for the treatment of cancer, bone and neurodegenerative diseases. Another novel lead chemical series is apratoxins, which target a novel mechanism of cotranslational translocation for the inhibition of growth factors and their receptors, such as VEGF and PDGF and their receptors. Multiple novel molecules in the apratoxin class have been discovered and shown excellent anti-proliferative and anti-angiogenic activities in animal models of cancer and have the potential to treat various angiogenic disorders. In addition, to these two novel chemical series, the Companyâs platform has identified several other lead chemical series targeting proteases and other targets.In preclinical studies, largazole and apratoxin S4 have shown excellent activity in colon cancer models and largazole has demonstrated excellent osteogenic, anti-fibrotic and anti-angiogenic activity in animal models. In the United States there are over 1.1 million colorectal cancer patients and it is estimated that each year, an additional 141,000 new cases of colorectal cancer are diagnose
